When Evidence Gap Becomes a Commercial Liability
The MENA evidence gap for selected portfolios is becoming a commercial liability for drugmakers that could have been prevented at the design stage.
Why Real-World Evidence Is Becoming the Missing Link Between Innovation and Patient Care in Oncology
Organizations that can generate and apply high-quality, clinically grounded evidence will be better positioned to close the gap between what is proven in trials and what is achieved in practice.
presented by
The Healthcare Payments Industry Has a Perception Problem
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
presented by
The Power of Real World Data to Study Women’s Health at Scale
A new report from Veradigm examines key clinical trends, comorbidity profiles, and treatment trends across adolescence, reproductive years, and peri-/post-menopause. Download it today!
presented by
How to Use Real-World Data to Improve Drug Development, Starting with the Patient Journey
A new eBook explores how using real world data from patients can help drug developers improve outcomes for non-small cell lung cancer and other patient populations.
presented by
How Real-World Data Is Reshaping the NSCLC Patient Journey
A new eBook, sponsored by PurpleLab, examines how a significant number of patients with non-small cell lung cancer miss out on optimal care due to gaps in biomarker testing, socioeconomic barriers, incomplete patient journey data, and what can be done to change that.
Blinded by Science: The Importance of RWD and Post-market Surveillance
When applied with a rigorous, subject-matter-expert guided process, AI-currated RWD is an essential resource giving life science organizations new power to monitor the diverse variety of ways drugs are actually utilized post-approval.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
Digital Innovation in Pharma: What Will 2026 Bring?
This year will be the turning point from AI “hype” to the adoption of meaningful AI and digital health solutions in pharma. Here four predictions.
presented by
The Role of RWD in Revolutionizing Clinical Trial Design
Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people.
presented by
SDOH in Oncology: Mapping Out How Zip Code Can Affect Care Is a Critical Step to Improving Outcomes
For non small cell lung cancer patients, a zip code can mean the difference between diagnosis time and treatment options.
presented by
Using RWD, SDoH and Patient Mapping to Eliminate Blind Spots from the Patient Journey
This article is part of a series on eliminating blind spots in the patient journey by leveraging real-world data.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
Augmenting Brain Power: Real-World Data, Advanced Analytics, and the Future of Clinical Trials
The application of AI technology is part of a carefully orchestrated effort dependent on human intelligence, and the collaboration of physicians, disease-specific specialists, nurses, data scientists, and technologists. Done right, these efforts can lead to profound benefits, and offer a promising future for clinical research and patient care.
Data Technology + RWD Are Positive for Rare Disease Treatment
Technology that offers tools that conform, de-identify, link and aggregate data and data science tools like AI, machine learning and advanced analytics, can help those researching rare diseases overcome the hurdles they face in discovery and development.
Harnessing Real-World Data and AI to Advance Research and Treatment for Benign Prostatic Hyperplasia
The ability to harness real-world insights at scale empowers life sciences companies and clinicians to develop more targeted therapies, improve patient outcomes, and drive evidence-based innovation in BPH treatment.
presented by
How Can RWD Transform the Patient Journey?
A one-size fits most approach to clinical trial recruitment is no longer effective. A webinar discussion emphasized the need for patient-level data to shape each phase of a drug’s lifecycle, from clinical development to market access.
presented by
Using RWD to Improve Clinical Trial Recruitment, Endpoints, and Inform Market Access Strategies
The webinar, sponsored by PurpleLab and scheduled for May 22, will explore how healthcare sector companies can leverage real world data (RWD) with a focus on lung cancer.